dpp-4 inhibitors and glp-1 agonists receptor or inhibitors: How to guide the clinician? Clinical Use of DPP-4 Inhibitors
Description
The importance of glucagon was also borne out by research carried out by Unger and Pierro Foa in Texas, Roger Assan and Gabby Rosselin in France and Pierre Lefebvre in Belgium
GLP-1 receptor agonists have rapidly emerged as one of the most important therapeutic breakthroughs in metabolic medicine
Injectable GLP-1 medications are delivered by a very small needle into the top fatty layer just beneath the skin
Pharmacologic approaches to glycemic treatment: standards of medical Care in diabetes2021
